Back

Real-world use and clinical outcomes among patients with atrial fibrillation using low-dose edoxaban and apixaban in Italy

1 April 2025 (08:00 - 14:15)
Organised by: Logo
Congress Presentation Part of: Poster session 3: clinical management of arrhythmias m-Health & Mobile Apps EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Rosa Wang

Daiichi Sankyo, Basking Ridge (United States of America)

139 More presentations in this session

Presentation thumbnail
The relationship between left atrial electroanatomical voltage mapping and CMR-based fibrosis for enhanced preplanning in atrial fibrillation ablation
Doctor Z. Dadon (Jerusalem, IL)
Abstract Slides Video
Presentation thumbnail
Cardiac sympathetic denervation for different cardiovascular indications - the experience of two referral centers
Doctor A. Zienciuk-Krajka (Gdansk, PL)
Abstract
Presentation thumbnail
Practicing physicians perception of feasibility and usefulness of quality indicators of treatment for atrial fibrillation
Doctor J. Simic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Risk of left atrial thrombus in patients undergoing catheter ablation for atrial fibrillation and atrial flutter
Assistant Professor F. Guerra (Ancona, IT)
Abstract Slides Video
Presentation thumbnail
Clustering analysis of left atrial smax patterns: predicting atrial fibrillation termination and associations with key clinical factors
Mr J. Huh (Seoul, KR)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3: clinical management of arrhythmias

The Event

Event poster

EHRA 2025

1 April 2025 08:00 CET
You may be interested in
thumbnail
Congress Presentation
From prescription to outcome: real-world utilization of direct oral anticoagulants in atrial fibrillation across Europe
thumbnail
Congress Presentation
The efficacy and safety of edoxaban compared to warfarin in patients with atrial fibrillation with different clinical phenotypes: a meta-analysis of randomized controlled trials
thumbnail
Congress Presentation
Impact of different dose reduction criteria on dose assignment of current DOACs and related outcomes: an analysis from 4-year data of the ETNA-AF Europe programme

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources